(Q46964940)

26 December 2017

title

Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy (English)

1 reference

26 December 2017

0 references

1 reference

M Chianelli

1

1 reference

26 December 2017

M G Parisella

2

1 reference

26 December 2017

N Visalli

3

1 reference

26 December 2017

S J Mather

4

1 reference

26 December 2017

C D'Alessandria

5

1 reference

26 December 2017

P Pozzilli

6

1 reference

26 December 2017

A Signore

7

1 reference

26 December 2017

IMDIAB study group

8

1 reference

26 December 2017

publication date

1 February 2008

1 reference

26 December 2017

Diabetes - Metabolism: Research and Reviews

published in

1 reference

26 December 2017

volume

24

1 reference

26 December 2017

issue

2

1 reference

26 December 2017

page(s)

115-122

1 reference

26 December 2017

The soluble interleukin-2 receptor: biology, function, and clinical application

cites work

1 reference

Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry.

21 January 2018

1 reference

7 January 2021

Type I diabetes mellitus. A chronic autoimmune disease

1 reference

7 January 2021

Immunological abnormalities in islets at diagnosis paralleled further deterioration of glycaemic control in patients with recent-onset Type I (insulin-dependent) diabetes mellitus.

1 reference

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

7 January 2021

Preventive and Therapeutic Effects of Large-Dose Nicotinamide Injections on Diabetes Associated with Insulitis: An Observation in Nonobese Diabetic (NOD) Mice

1 reference

7 January 2021

Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists

1 reference

7 January 2021

Systematic screening of potential beta-cell imaging agents

1 reference

7 January 2021

The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases

1 reference

7 January 2021

T cell growth factor receptors. Quantitation, specificity, and biological relevance

1 reference

7 January 2021

Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet

1 reference

7 January 2021

Detection of activated lymphocytes in endocrine pancreas of BB/W rats by injection of 123I-interleukin-2: an early sign of type 1 diabetes

1 reference

7 January 2021

New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123I-labelled interleukin 2

1 reference

7 January 2021

A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI).

1 reference

7 January 2021

Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes

1 reference

7 January 2021

Insulin autoantibodies in the pre-diabetic period: correlation with islet cell antibodies and development of diabetes

1 reference

7 January 2021

Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers

1 reference

7 January 2021

Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes.

1 reference

7 January 2021

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

1 reference

7 January 2021

Trapping of peripheral blood lymphocytes in the pancreas of patients with acute-onset insulin-dependent diabetes mellitus

1 reference

7 January 2021

Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes

1 reference

7 January 2021

Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time.

1 reference

7 January 2021

The Soluble Receptor of Interleukin 2 is Not a Serum Marker of the Autoimmune Activity in Type I Diabetes Mellitus

1 reference

7 January 2021

Accumulation of(125)iodine labeled interleukin-2 in the pancreas of NOD mice

1 reference

7 January 2021

I-interleukin-2 scintigraphy: a new approach to assess disease activity in autoimmunity

1 reference

7 January 2021

Benign versus destructive insulitis.

1 reference

7 January 2021

The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group

1 reference

7 January 2021

Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).

1 reference

7 January 2021

Type 1 diabetes--does suppressing T cells increase insulin?

1 reference

7 January 2021

Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: a population-based study. IMDIAB Study Group. Immunotherapy Diabetes.

1 reference

7 January 2021

Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM

1 reference

7 January 2021

Autoimmunity to islet proteins in children diagnosed with new-onset diabetes

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.767

1 reference

26 December 2017

1 reference

26 December 2017